BROOMFIELD, Colo., Aug. 14 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed William R. Hiatt, MD, as Director of Clinical and Regulatory Strategy. In this newly created position, Dr. Hiatt will be responsible for developing strategic regulatory and clinical initiatives designed to support the company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator in late-stage development for heart failure, as well as other compounds in ARCA's pipeline.
"Dr. Hiatt is a recognized expert who knows cardiovascular medicine from virtually every angle: as researcher, physician, educator, clinician and former advisor to the U.S. Food and Drug Administration," said Richard B. Brewer, president and chief executive officer of ARCA biopharma. "He brings valuable experience and insight to ARCA as we prepare to introduce our first product and begin to educate the medical community about the benefits of genetically targeted treatment of heart failure."
"I look forward to working with the talented men and women at ARCA to bring important new solutions to heart failure patients," said Dr. William Hiatt. "By inaugurating the personalized medicine trail in the heart failure arena, ARCA is changing the way we offer treatment to patients with this serious chronic condition."
Dr. Hiatt is Professor of Medicine, Professor of Cardiovascular
Research and Chief of the Section of Vascular Medicine at the University of
Colorado Denver's Anschutz Medical Campus. Throughout his career, Dr.
Hiatt's research has focused on developing new therapies for patients with
peripheral arterial disease and understanding its pathophysiology in terms
of the effects of muscle ischemia on muscle metabolism and function. Dr.
Hiatt also is President of the Colorado Preventio
|SOURCE ARCA biopharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved